ClinicalTrials.gg
CompletedNCT01726933Updated Dec 2, 2015

LAS41008 in Moderate to Severe Chronic Plaque Psoriasis

A Phase 3 interventional study of LAS41008 and LASW1835 in Plaque Psoriasis, sponsored by Almirall, S.A.. Completed at 4 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-02.

Sponsored by Almirall, S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
839
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Psoriasis by Almirall, S.A. — 2 open to participants now, 3 under way, none of them phase 3. Psoriasis · Almirall, S.A..

Enrollment
Largest of 14
839 · median 36
Started
2012
the only one that year
Phase 3
3 of 20
none open now
Registered
5th of 20
by date

Among the 20 studies in Psoriasis by Almirall, S.A., this one has the largest enrollment of the 14 interventional ones that give a count, is the only one that started in 2012, is one of 3 in phase 3, and was the 5th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 20 studies in Psoriasis by Almirall, S.A. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Psoriasis by Almirall, S.A., or all of them as a file.
02

Study summary

The aim of the study is to evaluate the efficacy and safety of LAS41008 in comparison to active control and placebo in patients with moderate to severe chronic plaque psoriasis

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • psoriasis, systemic treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and personally dated written
  2. Male / female
  3. Aged 18 years or older
  4. With a diagnosis of chronic plaque psoriasis for at least 12 months before enrollment in the study
  5. With the severity of psoriasis defined as moderate to severe, as reflected in meeting all the following criteria:

    • PASI > 10
    • BSA (body surface area) > 10 %
    • PGA moderate to severe
  6. With general good health, or a stable medical condition not considered likely to interfere with the conduct of the clinical study, as determined by the investigator based upon results of medical history, laboratory results and physical examination
  7. Prior therapy with systemic drugs for psoriasis or naïve to systemic treatment but identified as a candidate for systemic treatment.
  8. With a complete record of at least 12 months of other previous topical and systemic treatments, if any
  9. Adhering to the following Topical treatment Wash-out Period Vitamin A analogues Vitamin D analogues Anthracene derivatives Tar Salicylic acid preparations 2 weeks Systemic treatment Biologics with antipsoriatic activity 3 months Conventional systemic antipsoriatic drugs and phototherapy 1 month medication (if not covered by any of the above treatments) Cytostatics 6 months Medications with known harmful influences on the kidneys 5 x halftime
  10. For females of : a negative serum pregnancy test at screening and willing to use highly effective methods of during the study period and for 60 days after the last dose of product. Additionally they must agree to have pregnancy tests while on study medication. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomized partner. Female patients will be considered to be of childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal ligation, or for at least two years.
  11. Males (including those who have had vasectomy) must agree to use barrier contraception while on study medication
  12. Willing to keep sun exposure reasonably constant and not to use tanning booths or other UV light sources for the duration of the trial

Exclusion criteria

Exclusion Criteria:

  1. For females: pregnant or lactating
  2. With a diagnosis of guttate, erythrodermic or pustular psoriasis
  3. With a hematological abnormality as follows: count \< 100,000/mm3, WBC count \< 3,000 cells/ mm3, lymphocyte count \< 1.000/µl, , hematocrit, or red blood cell count outside 30 % of the upper or lower limits of normal for the lab
  4. With a history of except for non melanoma skin cancer
  5. Suffering from significant gastrointestinal problems (ulcers, diarrhea, etc.)
  6. Known to have significant renal impairment
  7. Are detected to have abnormal liver enzymes >2x the
  8. With active infectious disease
  9. On systemic therapy with drugs that may interfere with the products taken within the defined
  10. With a history of alcohol or drug abuse
  11. Known -positive status or suffering from any other disease
  12. Known to be hypersensitive to ingredients of the investigational products
  13. Previous enrolled in this study or participating in any other drug investigational trial within the 30 days (or five half-lives whichever is longer) prior to enrolment.
  14. Not willing to give consent for transmission of personal "pseudonymised" data
  15. Unable to comply with the requirements of the study or who in the opinion of the investigator should not participate in the study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
839 participants (actual)

Study arms

  • Experimental
    LAS41008

    up to 6 tablets/ day for 16 weeks double blind treatment period, randomized gastric resistant tablet

    Drug: LAS41008

  • Placebo comparator
    Placebo

    up to 6 tablets/ day for 16 weeks randomized, double blind gastric resistant tablet

    Drug: Placebo

  • Active comparator
    LASW1835

    double blind, randomized gastric resistant tablet up to 6 tablets/ day for 16 weeks

    Drug: LASW1835

Interventions

  • gastric resistant tablet, weekly up-titration up to maximal tolerated dosage

    Also known as: Verum

  • DrugLASW1835

    gastric resistant tablet, weekly up-titration up to maximal tolerated dosage

    Also known as: Fumaderm initial/ Fumaderm

  • DrugPlacebo

    gastric resistant tablet, weekly up-titration up to maximal tolerated dosage

06

What researchers measure

Primary outcomes

  1. PASI 75

    Reduction of PASI by 75% from baseline to week 16

    Time frame: 16 weeks

  2. Physician Global Assessment, PGA

    Change in PGA from baseline to week 16

    Time frame: 16 weeks

Secondary outcomes

  1. Body Surface Area, BSA

    Change in BSA from baseline to week 3, 8, 16 and follow up

    Time frame: 16 weeks

  2. Dermatological Life Quality Index, DLQI

    Change in DLQI from baseline to week 3, 8, 16 and follow up

    Time frame: 16 weeks

  3. PASI 75

    Change in PASI 75 from baseline to week 3 and 8 and follow up

    Time frame: week 3 and 8

  4. PGA

    Change in PGA from baseline to week 3 and 8 and follow up

    Time frame: week 3 and 8

  5. Adverse events

    Ongoing safety profile over the course of the study (treatment phase and follow up)

    Time frame: ongoing

Other outcomes

  1. Patient Benefit Index, PBI

    Calculation of individual benefit from therapy, assessed by patient at week 16 and in follow up

    Time frame: week 16

07

Study locations

4 sites
  • Investigatives site names will not be disclosed to avoid competitive information. Specify at least one site as follows: Almirall Investigative Site
    Various, Austria
  • Investigatives site names will not be disclosed to avoid competitive information. Specify at least one site as follows: Almirall Investigative Site
    Various, Germany
  • Investigatives site names will not be disclosed to avoid competitive information. Specify at least one site as follows: Almirall Investigative Site
    Various, Netherlands
  • Investigatives site names will not be disclosed to avoid competitive information. Specify at least one site as follows:Almirall Investigative Site #
    Various, Poland
08

References and documents

Publications

  • Warren RB, Barker JNW, Van de Kerkhof P, Reich K, Mrowietz U. Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis. J Eur Acad Dermatol Venereol. 2019 Oct;33(10):e352-e353. doi: 10.1111/jdv.15644. Epub 2019 May 10. No abstract available. PubMed 31033034 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Oct 2014 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2012
First posted
Nov 15, 2012
Start
Nov 2012
Primary completionActual
Oct 2014
CompletionActual
Nov 2015
Last update
Dec 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01726933
Lead sponsor
Almirall, S.A.
Collaborators
Almirall Hermal GmbH, Harrison Clinical Research
Responsible party
Sponsor
First posted
Nov 15, 2012
Start date
Nov 2012
Primary completion
Oct 2014
Completion
Nov 2015
Last update
Dec 2, 2015

Study contacts

Ulrich Mrowietz, MD, Prof
principal investigator · University Medical Center, Schleswig-Holstein, Department of Dermatology, Schittenhelmstr. 7, 24105 Kiel, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion